Little headway has been made in developing a treatment for Alzheimer’s disease, but that could be changing.
Leading topics of the 2020 J.P. Morgan Healthcare Conference included a general lack of big deals, defining digital health, and biopharma’s diversity problem.
The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.
With the 2020 elections looming though, and lawmakers across the country drafting legislation aimed at curbing price increases, some companies are carefully examining the landscape as they approach pricing.
The price of prescription drugs was a central issue in last night’s Democratic presidential debate as candidates pointed out ways they would use the power of the federal government to lower the cost of medications in the United States.
Although there were some deals announced at the ongoing J.P. Morgan Healthcare Conference, biotech stocks appeared to slide slightly at the overall lack of business transactions, at least during the first day or two.
Here is a look at some of the top presentations expected at the 38th annual JP Morgan Healthcare Conference taking place January 13-16, 2020, in San Francisco.
Merck & Co. released data from KEYNOTE-181, a Phase III trial of Keytruda as a monotherapy for the second-line treatment of advanced or metastatic esophageal or esophagogastric junction carcinoma.